Veronica Gambillara Fonck

Partner

2022 - Current

CEO-and Co-Founder

2021 - 2022

CEO-Co-founder

2015 - 2021

LimmaTech Biologics is a biotech Company based on innovative platform to make bioconjugate. Former GlycoVaxyn, acquired by GSK in 2015, LimmaTech maintains a close relationship with GSK for the development of novel vaccines . Moreover, with the deep in-house expertise of glycoconjugation is also working in the therapeutic field.

Executive Director, Clinical and Regulatory Affairs

2012 - 2015

• Overall responsibility for designing and managing company’s drug development strategy and operations •Assessed and evaluated the early stage product portfolio, streamlined preclinical development and prioritised clinical development •Built and developed an effective operational clinical team, created partnerships with relevant academic institutions. Selected participants, built agenda and managed the meetings of the International Advisory Board, international Expert- and Investigator’s groups •Responsible for the regulatory submission process (IND/IMPD submission to FDA/EMEA and Swissmedic)

Director Business Development

2011 - 2012

Director Clinical and Regulatory Affairs

2009 - 2011

Manager Clinical Affairs

2007 - 2009

Design, Initiate and Conduct pre and post-market studies in Europe and US for medical device.

Project Manager

2006 - 2007

Research Assistant

2001 - 2005